LON:RENE ReNeuron Group (RENE) Share Price, News & Analysis GBX 3.38 -0.08 (-2.17%) (As of 02/5/2024) Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesInsider Trades About ReNeuron Group Stock (LON:RENE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ReNeuron Group alerts:Sign Up Key Stats Today's Range 3.28▼ 3.5050-Day Range 3.38▼ 3.3852-Week Range 3.28▼ 11.50Volume177,373 shsAverage Volume578,249 shsMarket Capitalization£1.93 millionP/E RatioN/ADividend Yield0.76%Price TargetN/AConsensus RatingN/A Company OverviewReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Receive RENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter. Email Address RENE Stock News HeadlinesReNeuron Group (LON:RENE) Shares Cross Below 200 Day Moving Average - Here's What HappenedOctober 24, 2024 | americanbankingnews.comTRADING UPDATES: PetroTal buys Peru's Block 131 for USD5.0 millionMay 17, 2024 | lse.co.uk625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)ReNeuron CFO steps down to pursue other opportunitiesApril 17, 2024 | lse.co.ukMedtech firm IQ Endoscopes plans to create 100 new jobs and raise millionsApril 2, 2024 | msn.comUpland Resources shares soar as company prepares for Sarawak drillingMarch 28, 2024 | lse.co.ukCompany given millions of public money in Welsh Gov's disastrous foray into biotech investments collapses into administrationMarch 22, 2024 | msn.comTRADING UPDATES: ReNeuron appoints administrators as rescue talks failMarch 20, 2024 | lse.co.ukSee More Headlines RENE Stock Analysis - Frequently Asked Questions How have RENE shares performed this year? ReNeuron Group's stock was trading at GBX 3.50 at the beginning of the year. Since then, RENE stock has decreased by 3.6% and is now trading at GBX 3.38. View the best growth stocks for 2024 here. How were ReNeuron Group's earnings last quarter? ReNeuron Group plc (LON:RENE) posted its quarterly earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share for the quarter, beating the consensus estimate of ($50.20) by $14.30. How do I buy shares of ReNeuron Group? Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR) and Sirius Minerals (SXX). Company Calendar Last Earnings7/20/2020Today11/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryTrading Current SymbolLON:RENE CUSIPN/A CIKN/A Webwww.reneuron.com Phone+44-20-38198400FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.09) Trailing P/E RatioN/A Forward P/E Ratio0.47 P/E GrowthN/ANet Income£-5,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-106.77% Return on Assets-37.91% Debt Debt-to-Equity Ratio14.25 Current Ratio1.51 Quick Ratio2.02 Sales & Book Value Annual Sales£783,000.00 Price / Sales2.46 Cash FlowGBX 5.55 per share Price / Cash Flow0.61 Book ValueGBX 4 per share Price / Book0.84Miscellaneous Outstanding Shares57,170,000Free FloatN/AMarket Cap£1.93 million OptionableNot Optionable Beta0.83 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (LON:RENE) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReNeuron Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ReNeuron Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.